id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_vvlzsj54cvf5de6ji6py6krqlm	Amish N. Raval	Management of Patients on Non–Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association	2017.0	30	.pdf	application/pdf	24145	2696	58	Management of Patients on Non–Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association risk of stroke, systemic embolism, major bleeding, and death compared with warfarin for NVAF.2–5 In contrast with warfarin, NOACs have a more predictable therapeutic clotting time.12 Case reports of patients with life-threatening bleeding associated with dabigatran therapy have In summary, the AHA writing group suggests that traumatic and nontraumatic ICH patients on dabigatran who require NOAC reversal receive idarucizumab. trials comparing the risk of thromboembolic events associated with temporary discontinuation found no statistically significant differences in the NOAC versus VKA Periprocedural bleeding was studied in a subgroup analysis of the RELY trial which compared warfarin to dabigatran for stroke prevention in NVAF.103 Apixaban Use in Association With Dual Antiplatelet Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention]134 and AUGUSTUS [A Study 	./cache/work_vvlzsj54cvf5de6ji6py6krqlm.pdf	./txt/work_vvlzsj54cvf5de6ji6py6krqlm.txt